Daiichi Sankyo

News

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress.

News

With $75m cash injection, SynOx plans ph3 rare tumour trial

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into ph

News

Roche gets EU okay for first HER2-low test kit

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for trea

News

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors a

News

AZ, Daiichi Sankyo file Dato-DXd for second indication

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

With $75m cash injection, SynOx plans ph3 rare tumour trial

Roche gets EU okay for first HER2-low test kit

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

AZ, Daiichi Sankyo file Dato-DXd for second indication

Surprise Enhertu rejection follows NICE process change

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Daiichi Sankyo

Editor's Picks